The Future Of Cell Therapy Development And Delivery

Six autologous CAR-T cell immunotherapy products have already been approved by the FDA since 2017 and a number of allogeneic cell therapies are in the development pipeline. As these transformative medicines enable the treatment of numerous serious or life-threatening diseases, it is critical for sponsors to optimize development and manufacturing processes with the goal of serving a wider patient population.

The elaborate, time-consuming process and high costs to develop cell therapies can stymie patients from receiving treatment in a timely manner. Improving the scalability of the manufacture for advanced therapies can help lower costs, and “off-the-shelf” methods that leverage healthy donor cells can help reduce treatment wait times.

This webinar convenes leading advanced therapy experts to discuss the future of cell therapy development and delivery. Learn more as experts discuss the latest strategies for navigating the complexities of cell therapy development and identify clinical development best practices for a successful execution.